The Future of PET Imaging Agents

EP: 1.The Evolvement of Imaging in ccRCC

EP: 2.The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses

EP: 3.Strengths and Weaknesses of Imaging Modalities in ccRCC

EP: 4.Treatment or Lack of Treatment of Small Renal Masses

EP: 5.Decision-Making in Small Renal Masses

EP: 6.Current Unmet Needs in ccRCC Diagnosis

EP: 7.Early Detection of ccRCC

EP: 8.Key Benefits of PET in ccRCC Risk Stratification

EP: 9.The ZIRCON Trial

EP: 10.The MOA of TLX250

EP: 11.Top-Line Results of the Phase 3 ZIRCON Study

EP: 12.Risk Stratification in ccRCC: The Impact in Patient Populations

EP: 13.Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging

EP: 14.Overcoming Challenges for Wider Adoption of TLX250

Now Viewing

EP: 15.The Future of PET Imaging Agents

EP: 16.The Logistical Challenges in ccRCC Treatment

Cytoreductive Nephrectomy and Molecular Imaging

Main Discussion Topics:

• Evolution away from routine cytoreductive nephrectomy in metastatic renal cell carcinoma (RCC)
• The current approach favors systemic therapy first in most metastatic cases.
• Potential for molecular imaging to identify patients who might not need surgery
• Possible role in identifying when to de-escalate systemic therapy

Key Points for Physicians:

• Systemic therapy generally precedes surgery in contemporary metastatic RCC management.
• Molecular imaging could identify patients with complete molecular response who might avoid surgery.
• Could help distinguish active disease from posttreatment artifacts on conventional imaging
• May guide therapy de-escalation decisions in responding patients

Notable Insights:

Molecular imaging could potentially identify patients with complete biological response despite persistent radiographic abnormalities, potentially sparing them unnecessary surgery.

Clinical Significance:

This technology has applications beyond initial diagnosis and could fundamentally change how we assess treatment response and make subsequent therapy decisions.